Constellation Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Constellation Pharmaceuticals's estimated annual revenue is currently $28.3M per year.
- Constellation Pharmaceuticals received $100.0M in venture funding in April 2018.
- Constellation Pharmaceuticals's estimated revenue per employee is $201,000
- Constellation Pharmaceuticals's total funding is $496.2M.
Employee Data
- Constellation Pharmaceuticals has 141 Employees.
- Constellation Pharmaceuticals grew their employee count by -14% last year.
Constellation Pharmaceuticals Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 347 | -5% | $634M | N/A |
#2 | $50.9M | 253 | N/A | N/A | N/A |
#3 | $39.6M | 197 | -12% | N/A | N/A |
#4 | $11.6M | 214 | 0% | $506.4M | N/A |
#5 | $4360M | 37257 | 175% | N/A | N/A |
#6 | $16.3M | 81 | N/A | N/A | N/A |
#7 | $37.2M | 185 | N/A | N/A | N/A |
#8 | $3.2M | 16 | N/A | N/A | N/A |
#9 | $5.6M | 28 | -3% | N/A | N/A |
#10 | $888.2M | 4419 | 0% | N/A | N/A |
What Is Constellation Pharmaceuticals?
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression. Our integrated epigenetics platform enables us to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. We are able to target a broad variety of epigenetic regulators using our platform and have generated development candidates acting against distinct classes of those regulators.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$496.2M
Total Funding
141
Number of Employees
$28.3M
Revenue (est)
-14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Constellation Pharmaceuticals News
DGAP-News: MorphoSys AG / Key word(s): Mergers & Acquisitions MorphoSys to Acquire Constellation Pharmaceuticals 02.06.2021 / 13:24 The issuer is solely responsible for the content of this announcement. MorphoSys to Acquire Constellation Pharmaceuticals Accelerates Growth Strategy by Adding ...
Ad hoc release according to article 17 para. 1 MAR Planegg/Munich, Germany and Cambridge, Mass., June 2, 2021 Ad hoc: MorphoSys to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma MorphoSys AG (FSE: MOR; NASDAQ: MOR) ("MorphoSys"), announ ...
MorphoSys to Acquire Constellation Pharmaceuticals Accelerates Growth Strategy by Adding Two Mid- to Late-Stage Product Candidates: Pelabresib (CPI-0610) and CPI-0209 Bolsters Position in Hematology-Oncology and Expands into Solid Tumors Best-in-Class Combined Discovery and Development Capab ...
Wall Street analysts expect Constellation Pharmaceuticals Inc (NASDAQ:CNST) to report earnings per share of ($0.81) for the current fiscal ...
CAMBRIDGE, Mass., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (CNST), a clinical-stage biopharmaceutical ...
We see here that Constellation Pharmaceuticals, Inc. (:CNST) is -2.10% away from the 20-Day Simple Moving Average. Their 50-Day Simple ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $22M | 142 | 28% | $333.5M |
#2 | $25.5M | 142 | 6% | N/A |
#3 | $45.3M | 142 | 2% | N/A |
#4 | $22.6M | 142 | 6% | N/A |
#5 | $20M | 143 | 14% | $119.7M |
Constellation Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2008-04-30 | $32.0M | A | Third Rock Ventures, The Column Group | Article |
| 2010-06-04 | $22.0M | B | SR One | Article |
| 2011-06-07 | $15.0M | B | Multiple | Article |
| 2014-08-07 | $5.0M | Undisclosed | Multiple | Article |
| 2015-12-11 | $55.0M | Undisclosed | Article | |
| 2018-04-10 | $100.0M | Undisclosed | Multiple | Article |
